Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 29, 2016

Primary Completion Date

September 10, 2018

Study Completion Date

July 12, 2021

Conditions

Breast CancerEstrogen Receptor Positive Breast Cancer

Interventions

DRUG

entinostat

An orally available histone deacetylases inhibitor (HDAC)

DRUG

exemestane

Aromatase inhibitor

Trial Locations (3)

Florida Cancer Specialists, Sarasota

Sarah Cannon Research Institute, Nashville

Sarah Cannon Research Institute HealthONE, Denver